research Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
Search
for
Sort by
Research
60-90 / 1000+ results 
research PSS20 MEDIATION MODELING AND MEASUREMENT CHARACTERISTICS OF THE ITCH SEVERITY SCORE FROM A PHASE 2B TRIAL OF ORAL CP-690-550 IN PATIENTS WITH MODERATE TO-SEVERE PLAQUE PSORIASIS
CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
research Successful rapid subcutaneous desensitization to anakinra in a case of delayed‐type hypersensitivity reaction
A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.
research 0480 Upadacitinib monotherapy for treatment of pyoderma gangrenosum: A case series
Upadacitinib effectively treats pyoderma gangrenosum.
research 265 Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis
TAK-279 effectively reduces psoriasis symptoms and is safe.
research Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
research A Case of Steatocystoma Multiplex in a Psoriatic Patient during Treatment with Anti-IL-12/23
Ustekinumab treatment may reveal a genetic tendency for steatocystoma multiplex in psoriasis patients.
research 269 Down-regulatory role of cholecystokinin on psoriatic epidermal inflammation
Cholecystokinin may help reduce skin inflammation in psoriasis.
research Alopecia areata in a patient with psoriatic arthritis and C rohn's disease receiving etanercept
Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.
research Targeting noncanonical nuclear factor kappa B signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alpha
Topical IKKα inhibitors may help prevent CCS tumours.
research S3909 Paradoxical Psoriasis and Alopecia Areata After the Use of Anti-TNF in a Patient With Crohn's Cisease
Switching from infliximab to Ustekinumab improved both hair loss and Crohn's symptoms in the patient.
research Hair whitening in a patient with psoriasis on adalimumab reversed after switching to ixekizumab
Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.
research Cutaneous Crohn's disease treated with infliximab and 4 years of follow up
Infliximab improved skin and bowel symptoms in Crohn's disease but caused side effects and the disease returned after stopping treatment.
research Alopecia areata as an immune-related adverse event associated with response to immune checkpoint inhibitors
Brodalumab is more effective than ustekinumab for treating psoriasis.
research Real-world single-center experience with 10 cases of generalized pustular psoriasis successfully treated with ixekizumab
Ixekizumab effectively treats generalized pustular psoriasis.
research Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors and baricitinib: A case report and literature review
A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
research Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review
Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
research Biologics in the management of childhood atopic dermatitis
Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
research Alopecia areata after dupilumab for atopic dermatitis
Dupilumab for eczema may cause hair loss.
research Editorial: Exploring innovative therapies for rare inflammatory skin diseases
New therapies for rare skin diseases show promise but need more research.
research Salivary Gland Inflammation During Acitretin Therapy for Generalized Pustular Psoriasis: a Case Report and Diagnostic Challenge
Acitretin may cause salivary gland inflammation.
research Reporting on Adverse Clinical Events
The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.
research Highlights
Acne is not a key diagnostic feature for PCOS, postadolescent men with acne may have insulin resistance, melanoma patients often have few moles, tumor size in CSCC indicates higher risk of serious outcomes, and hidradenitis suppurativa is linked to higher risk of heart problems and death.
research P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research USE OF UPADACITINIB IN 2 CASES OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research Treatment of discoid lupus erythematosus scarring alopecia with deucravacitinib: A case report
Deucravacitinib helped regrow hair and reduce plaques in a woman with discoid lupus erythematosus without side effects.
research Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
research 24 ARQ-234: a high affinity CD200-Fc fusion protein for the treatment of atopic dermatitis
ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
research Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Adalimumab significantly improved Hidradenitis Suppurativa and quality of life in two patients.